Dominic De Angelo, Internal Medicine - Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2000 |
Dr. Antoinette Spevetz, M.D. Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Critical Care Unit, Camden, NJ 08103 Phone: 856-342-2657 Fax: 856-968-8306 |
Caitlin Marie Baldwin, Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2000 Fax: 856-968-8282 |
David R. Gerber, DO Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Dorrance 432, Camden, NJ 08103 Phone: 856-342-2657 Fax: 856-968-8306 |
Dr. Adam Godfrey Green, M.D., M.B.A. Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2000 |
Dr. Mazen Pierre Kreidy, MD Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-448-3051 |
Mariane Charron, M.D. Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2000 |
News Archive
It is now possible to determine which patients have an increased chance of one day needing life support with mechanical ventilation. Researchers have developed a simple tool to predict an individual's five-year risk of requiring this care.
A new study suggests that blocking an enzyme called PRMT5 in tumor cells could be a promising new strategy for the treatment of glioblastoma (GB), the most aggressive and lethal form of brain cancer.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload technology, today announced the reporting of the first data on the Company's IMGN853 product candidate for the treatment of ovarian cancer and other types of solid tumors.
Sanofi announced today data from four studies of its once-daily GLP-1 receptor agonist Lyxumia that is in Phase III clinical development, including data that demonstrates positive results in type 2 diabetes patients not at goal on oral therapies or with basal insulin.
BioDelivery Sciences International, Inc. announced the positive outcome of a meeting with the FDA on the development program for BEMA Granisetron, the company's potential treatment for the prevention of nausea and vomiting associated with cancer therapy. FDA concurred with BDSI's plans to pursue a development program based on clinical pharmacokinetic data for a 505(b)(2) New Drug Application.
› Verified 1 days ago